Compassionate use study of caspofungin in children with proven or suspected invasive mycosis or persistent febrile neutropenia

Journal of Chemotherapy

Volumn 21, Issue 2, 2009, Pages 229-231

  Madero, L ^a   Sanchez De Toledo, J ^b   Castel, V ^c   Sevilla, J ^a   Gonzalez Esteban, J ^d   Sanz Rodriguez, C ^d  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d Medical affairs Merck sharp and Dohme ltd   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN A; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIMICROBIAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPOKALEMIA; INFECTION RISK; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYCOSIS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SPAIN; URTICARIA;

EID: 67249091012     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.2.229     Document Type: Article

References (14)

1. Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003; 51: 513-521.
2. Keating GM, Jarvis B. Caspofungin. Drugs. 2001; 61: 1121-129.
3. Cancer Therapy Evaluation Program. Common Toxicity Criteria. National Cancer Institute, Version 2.0, June 1, 1999. Available online at http://www.rtog.org/members/toxicity/ctc-manual6-l-99.pdf.
4. Castagnola E, Machetti M, Cappelli B, et al. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogenic bone marrow transplant. Clin Microbiol Infect 2004; 10:255-257.
5. Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 2003; 22: 747-749.
6. Cesaro S, Giacchino M, Locatelli F, et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BCM Infect Dis 2007; 7: 38, doi: 10.1186/1471-2334-7-28.
7. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23:1093-1097.
8. Cesaro S, Toffolutti T, Messina C, et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004;73:50-55.
9. Sallmann S, Heilmann A, Heinke F, et al. Capofungin therapy for Aspergillus lung infection in a boy with chronic granulo-matous disease. Pediatr Infect Dis J 2003;22:199-203.
10. Wertz KK, Pretzlaff RK. Caspofungin in a pediatric patient with persistent candidemia. Pediatr Crit Care Med 2004; 5: 181-183.
11. Natarajan G, G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005; 25: 770-777.
12. Groll AH, Attarbaschi A, Schuster FR, et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother 2006;57:527-35.
13. Merlin E, Galambrun C, Ribaud P, et al. Efficacy and safety of caspofungin therapy in children with invasive fungal infections. Pediatr Infect Dis J 2006;25:1186-1188.
14. Koo A, Sung L, Upton A, et al. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children. Pediatr Infect Dis J 2007;26:854-856.